• Bone Therapeutics provides update on the progress of clinical studies

    Monday July 19th 2021

  • Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

    Thursday July 15th 2021

  • Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation

    Thursday July 15th 2021

  • Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump® study (POSEIDON)

    Thursday July 1st 2021

  • Mithra completes recruitment of Covid-19 Phase II Study

    Thursday June 17th 2021

  • Precigen ActoBio announces positive topline results from Phase 1b/2a Study of AG019 ActoBiotics™

    Monday June 14th 2021

  • SELECTION study on filgotinib in ulcerative colitis published in The Lancet

    Friday June 4th 2021

  • Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting

    Wednesday May 19th 2021

  • Your news here?

  • Sequana Medical announces strong top-line results from RED DESERT alfapump DSR® study and expansion of DSR® development programme

    Tuesday May 11th 2021

  • New cancer immunotherapy treatment enters clinical phase

    Thursday April 29th 2021

  • Precirix partners with Evergreen to expand North American clinical trial supply

    Wednesday April 28th 2021


Strategic Partners